Anand, Nimay C.
Takaichi, Mika
Johnson, Emma F.
Wetter, David A.
Davis, Mark D. P.
Alavi, Afsaneh http://orcid.org/0000-0003-1171-4917
Funding for this research was provided by:
School of Medicine, Vanderbilt University
Article History
Accepted: 8 June 2022
First Online: 18 July 2022
Declarations
:
: Nimay Anand is funded by the Vanderbilt Medical Scholars Program. No other funding sources were used to assist in the preparation of this article.
: Afsaneh Alavi is an investigator for Boehringer Ingelheim and Processa Pharmaceuticals, and a consultant for AbbVie, Boehringer Ingelheim, InflaRx, Novartis, and UCB. Nimay C. Anand, Mika Takaichi, Emma F. Johnson, David A. Wetter, and Mark D.P. Davis have no conflicts of interest to declare.
: All data generated and/or analyzed during this study are included in this published article (and its supplementary information files).
: Not applicable.
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Mayo Clinic Institutional Review Board (#20-010125).
: The Mayo Clinic Institutional Review Board approved the study and waived written informed consent for those who provided research authorization.
: Not applicable.
: Concept and design: EFJ, DAW, AA. Acquisition, analysis, or interpretation of data: NCA, EFJ, AA. Drafting of the manuscript: NCA, AA. Critical revision of the manuscript: All authors.